Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):537–540. doi: 10.1038/bjc.1994.97

A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer.

S Kehoe 1, C J Poole 1, A Stanley 1, H M Earl 1, G R Blackledge 1
PMCID: PMC1968837  PMID: 8123484

Abstract

A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF, 3-5 micrograms kg-1 day-1, days 3-14, but one of these suffered a toxic death on study. Another died of disease progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were withdrawn because of various rH GM-CSF-related problems. Although potentially affording some patients the hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of chemotherapy, this regimen is not without problems.

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328–340. doi: 10.7326/0003-4819-64-2-328. [DOI] [PubMed] [Google Scholar]
  2. Calvert A. H. Combining cisplatin and carboplatin complementary or contradictory? Ann Oncol. 1991 Feb;2(2):89–91. doi: 10.1093/oxfordjournals.annonc.a057889. [DOI] [PubMed] [Google Scholar]
  3. Devereux S., Linch D. C., Campos Costa D., Spittle M. F., Jelliffe A. M. Transient leucopenia induced by granulocyte-macrophage colony-stimulating factor. Lancet. 1987 Dec 26;2(8574):1523–1524. doi: 10.1016/s0140-6736(87)92654-7. [DOI] [PubMed] [Google Scholar]
  4. Gianni A. M., Bregni M., Siena S., Orazi A., Stern A. C., Gandola L., Bonadonna G. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol. 1990 May;8(5):768–778. doi: 10.1200/JCO.1990.8.5.768. [DOI] [PubMed] [Google Scholar]
  5. Gribben J. G., Devereux S., Thomas N. S., Keim M., Jones H. M., Goldstone A. H., Linch D. C. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet. 1990 Feb 24;335(8687):434–437. doi: 10.1016/0140-6736(90)90665-r. [DOI] [PubMed] [Google Scholar]
  6. Hryniuk W. M., Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990 Dec;8(12):1935–1937. doi: 10.1200/JCO.1990.8.12.1935. [DOI] [PubMed] [Google Scholar]
  7. Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C., Cruickshank D. J., Atkinson R. J., Soukop M., Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329–333. doi: 10.1016/0140-6736(92)91404-v. [DOI] [PubMed] [Google Scholar]
  8. Lieschke G. J., Cebon J., Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1989 Dec;74(8):2634–2643. [PubMed] [Google Scholar]
  9. Lieschke G. J., Maher D., Cebon J., O'Connor M., Green M., Sheridan W., Boyd A., Rallings M., Bonnem E., Metcalf D. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med. 1989 Mar 1;110(5):357–364. doi: 10.7326/0003-4819-110-5-357. [DOI] [PubMed] [Google Scholar]
  10. Lieschke G. J., Maher D., O'Connor M., Green M., Sheridan W., Rallings M., Bonnem E., Burgess A. W., McGrath K., Fox R. M. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res. 1990 Feb 1;50(3):606–614. [PubMed] [Google Scholar]
  11. Lund B., Hansen M., Hansen O. P., Hansen H. H. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol. 1989 Oct;7(10):1469–1473. doi: 10.1200/JCO.1989.7.10.1469. [DOI] [PubMed] [Google Scholar]
  12. Metcalf D., Burgess A. W., Johnson G. R., Nicola N. A., Nice E. C., DeLamarter J., Thatcher D. R., Mermod J. J. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol. 1986 Sep;128(3):421–431. doi: 10.1002/jcp.1041280311. [DOI] [PubMed] [Google Scholar]
  13. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  14. Ngan H. Y., Choo Y. C., Cheung M., Wong L. C., Ma H. K., Collins R., Fung C., Ng C. S., Wong V., Ho H. C. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy. 1989;35(3):221–227. doi: 10.1159/000238673. [DOI] [PubMed] [Google Scholar]
  15. Owen W. F., Jr, Rothenberg M. E., Silberstein D. S., Gasson J. C., Stevens R. L., Austen K. F., Soberman R. J. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med. 1987 Jul 1;166(1):129–141. doi: 10.1084/jem.166.1.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sieff C. A., Emerson S. G., Donahue R. E., Nathan D. G., Wang E. A., Wong G. G., Clark S. C. Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. Science. 1985 Dec 6;230(4730):1171–1173. doi: 10.1126/science.3877981. [DOI] [PubMed] [Google Scholar]
  17. Tanikawa S., Nakao I., Tsuneoka K., Nara N. Effects of recombinant granulocyte colony-stimulating factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice. Exp Hematol. 1989 Sep;17(8):883–888. [PubMed] [Google Scholar]
  18. de Vries E. G., Biesma B., Willemse P. H., Mulder N. H., Stern A. C., Aalders J. G., Vellenga E. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res. 1991 Jan 1;51(1):116–122. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES